6 O
ADVERSE O
REACTIONS O
Detailed O
information O
on O
serious O
and O
adverse O
reactions O
of O
particular O
importance O
is O
provided O
in O
the O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5 O
) O
sections O
: O
* O
Drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
] O
* O
Hypersensitivity B-Not_AE_Candidate
to O
Methylphenidate O
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
* O
Marked O
anxiety B-Not_AE_Candidate
, O
tension B-Not_AE_Candidate
, O
or O
agitation B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.2 O
) O
] O
* O
Glaucoma B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.3 O
) O
] O
* O
Tics B-Not_AE_Candidate
or O
a O
family O
history O
of O
Tourette B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.4 O
) O
] O
* O
Monoamine O
Oxidase O
Inhibitors O
[ O
see O
Contraindications O
( O
4.5 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
* O
Serious O
Cardiovascular B-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Psychiatric B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Priapism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Vasculopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Long-Term O
Suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Growth I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Chemical B-OSE_Labeled_AE
Leukoderma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Contact B-OSE_Labeled_AE
Sensitization I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Visual B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
External B-NonOSE_AE
Heat I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Hematologic B-NonOSE_AE
Monitoring O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
The O
most O
commonly O
reported O
( O
frequency O
> O
= O
5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
adverse O
reactions O
in O
a O
controlled O
trial O
in O
children O
aged O
6-12 O
included O
appetite B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
tic B-OSE_Labeled_AE
, O
affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
and O
anorexia B-OSE_Labeled_AE
. O

The O
most O
commonly O
reported O
( O
frequency O
> O
= O
5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
adverse O
reactions O
in O
a O
controlled O
trial O
in O
adolescents O
aged O
13-17 O
were O
appetite B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
anorexia B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
most O
common O
( O
> O
= O
2 O
% O
of O
subjects O
) O
adverse O
reaction O
associated O
with O
discontinuations O
in O
double-blind O
clinical O
trials O
in O
children O
or O
adolescents O
was O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
overall O
Daytrana O
development O
program O
included O
exposure O
to O
Daytrana O
in O
a O
total O
of O
2,152 O
participants O
in O
clinical O
trials O
, O
including O
1,529 O
children O
aged O
6-12 O
, O
223 O
adolescents O
aged O
13-17 O
, O
and O
400 O
adults O
. O

The O
1,752 O
child O
and O
adolescent O
subjects O
aged O
6-17 O
years O
were O
evaluated O
in O
10 O
controlled O
clinical O
studies O
, O
7 O
open-label O
clinical O
studies O
, O
and O
5 O
clinical O
pharmacology O
studies O
. O

In O
a O
combined O
studies O
pool O
of O
children O
using O
Daytrana O
with O
a O
wear O
time O
of O
9 O
hours O
, O
212 O
subjects O
were O
exposed O
for O
> O
= O
6 O
months O
and O
115 O
were O
exposed O
for O
> O
= O
1 O
year O
; O
85 O
adolescents O
have O
been O
exposed O
for O
> O
= O
6 O
months O
. O

Most O
patients O
studied O
were O
exposed O
to O
Daytrana O
patch O
sizes O
of O
12.5 O
cm O
2 O
, O
18.75 O
cm O
2 O
, O
25 O
cm O
2 O
or O
37.5 O
cm O
2 O
, O
with O
a O
wear O
time O
of O
9 O
hours O
. O

In O
the O
data O
presented O
below O
, O
the O
adverse O
reactions O
reported O
during O
exposure O
were O
obtained O
primarily O
by O
general O
inquiry O
at O
each O
visit O
, O
and O
were O
recorded O
by O
the O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
reactions O
without O
first O
grouping O
similar O
types O
of O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

Throughout O
this O
section O
adverse O
reactions O
reported O
are O
events O
that O
were O
considered O
to O
be O
reasonably O
associated O
with O
the O
use O
of O
Daytrana O
based O
on O
comprehensive O
assessment O
of O
the O
available O
adverse O
event O
information O
. O

A O
causal O
association O
for O
Daytrana O
often O
can O
not O
be O
reliably O
established O
in O
individual O
cases O
. O

Further O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

EXCERPT O
: O
* O
Children O
( O
ages O
6-12 O
) O
: O
The O
most O
commonly O
( O
> O
=5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
reported O
adverse O
reactions O
in O
a O
placebo-controlled O
trial O
in O
children O
aged O
6-12 O
included O
appetite O
decreased O
, O
insomnia O
, O
nausea O
, O
vomiting O
, O
weight O
decreased O
, O
tic O
, O
affect O
lability O
, O
and O
anorexia O
( O
6.1 O
) O
. O

* O
Adolescents O
( O
ages O
13-17 O
) O
: O
The O
most O
commonly O
( O
> O
=5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
reported O
adverse O
reactions O
in O
a O
placebo-controlled O
trial O
in O
adolescents O
aged O
13-17 O
included O
appetite O
decreased O
, O
nausea O
, O
insomnia O
, O
weight O
decreased O
, O
dizziness O
, O
abdominal O
pain O
, O
and O
anorexia O
. O

The O
majority O
of O
subjects O
in O
these O
trials O
had O
erythema O
at O
the O
application O
site O
( O
6.1 O
) O
. O

* O
The O
most O
common O
( O
> O
=2 O
% O
of O
subjects O
) O
adverse O
reaction O
associated O
with O
discontinuations O
in O
controlled O
clinical O
trials O
in O
children O
or O
adolescents O
was O
application O
site O
reactions O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Noven O
Therapeutics O
, O
LLC O
at O
1-877-567-7857 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Adverse O
Reactions O
Associated O
With O
Discontinuation O
of O
Treatment O
In O
a O
7-week O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
study O
in O
children O
with O
ADHD B-Not_AE_Candidate
conducted O
in O
the O
outpatient O
setting O
, O
7.1 O
% O
( O
7/98 O
) O
of O
patients O
treated O
with O
Daytrana O
discontinued O
due O
to O
adverse O
events O
compared O
with O
1.2 O
% O
( O
1/85 O
) O
receiving O
placebo O
. O

The O
most O
commonly O
reported O
( O
> O
= O
1 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
adverse O
reactions O
leading O
to O
discontinuation O
in O
the O
Daytrana O
group O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
tics B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
irritability B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

In O
a O
7-week O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
study O
in O
adolescents O
with O
ADHD B-Not_AE_Candidate
conducted O
in O
the O
outpatient O
setting O
, O
5.5 O
% O
( O
8/145 O
) O
of O
patients O
treated O
with O
Daytrana O
discontinued O
due O
to O
adverse O
reactions O
compared O
with O
2.8 O
% O
( O
2/72 O
) O
receiving O
placebo O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
leading O
to O
discontinuation O
in O
the O
Daytrana O
group O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
2 O
% O
) O
and O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
/ O
anorexia B-OSE_Labeled_AE
( O
1.4 O
% O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Skin B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
and O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Daytrana O
is O
a O
dermal B-OSE_Labeled_AE
irritant I-OSE_Labeled_AE
. O

In O
addition O
to O
the O
most O
commonly O
reported O
adverse O
reactions O
presented O
in O
Table O
2 O
, O
the O
majority O
of O
subjects O
in O
those O
studies O
had O
minimal O
to O
definite O
skin B-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
patch I-OSE_Labeled_AE
application I-OSE_Labeled_AE
site I-OSE_Labeled_AE
. O

This O
erythema B-NonOSE_AE
generally O
caused O
no O
or O
minimal O
discomfort O
and O
did O
not O
usually O
interfere O
with O
therapy O
or O
result O
in O
discontinuation O
from O
treatment O
. O

Erythema B-NonOSE_AE
is O
not O
by O
itself O
a O
manifestation O
of O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
. O

However O
, O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
should O
be O
suspected O
if O
erythema B-NonOSE_AE
is O
accompanied O
by O
evidence O
of O
a O
more O
intense O
local B-NonOSE_AE
reaction I-NonOSE_AE
( O
edema I-NonOSE_AE
, O
papules O
, O
vesicles O
) O
that O
does O
not O
significantly O
improve O
within O
48 O
hours O
or O
spreads O
beyond O
the O
patch O
site O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Most O
Commonly O
Reported O
Adverse O
Reactions O
Table O
2 O
lists O
treatment-emergent O
adverse O
reactions O
reported O
in O
> O
= O
1 O
% O
Daytrana-treated O
children O
or O
adolescents O
with O
ADHD O
in O
two O
7 O
week O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
studies O
conducted O
in O
the O
outpatient O
setting O
. O

Overall O
, O
in O
these O
studies O
, O
75.5 O
% O
of O
children O
and O
78.6 O
% O
of O
adolescents O
experienced O
at O
least O
1 O
adverse O
event O
. O

* O
Six O
subjects O
had O
affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
all O
judged O
as O
mild O
and O
described O
as O
increased B-OSE_Labeled_AE
emotionally I-OSE_Labeled_AE
sensitive I-OSE_Labeled_AE
, O
emotionality B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
instability I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
and O
intermittent B-OSE_Labeled_AE
emotional I-OSE_Labeled_AE
Table O
2 O
Number O
( O
% O
) O
of O
Subjects O
with O
Commonly O
Reported O
Adverse O
Reactions O
( O
> O
= O
1 O
% O
in O
the O
Daytrana O
Group O
) O
in O
7-Week O
Placebo-controlled O
Studies O
in O
Either O
Children O
or O
Adolescents O
- O
Safety O
Population O
Adolescents O
Children O
System O
Organ O
Class O
Preferred O
term O
PlaceboN O
= O
72 O
DaytranaN O
= O
145 O
PlaceboN O
= O
85 O
DaytranaN O
= O
98 O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Tachycardia B-OSE_Labeled_AE
0 O
( O
0 O
) O
1 O
( O
0.7 O
) O
0 O
( O
0 O
) O
1 O
( O
1.0 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0 O
( O
0 O
) O
7 O
( O
4.8 O
) O
5 O
( O
5.9 O
) O
7 O
( O
7.1 O
) O
Nausea B-OSE_Labeled_AE
2 O
( O
2.8 O
) O
14 O
( O
9.7 O
) O
2 O
( O
2.4 O
) O
12 O
( O
12.2 O
) O
Vomiting B-OSE_Labeled_AE
1 O
( O
1.4 O
) O
5 O
( O
3.4 O
) O
4 O
( O
4.7 O
) O
10 O
( O
10.2 O
) O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
1 O
( O
1.4 O
) O
8 O
( O
5.5 O
) O
0 O
( O
0 O
) O
9 O
( O
9.2 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
1 O
( O
1.4 O
) O
7 O
( O
4.8 O
) O
1 O
( O
1.2 O
) O
5 O
( O
5.1 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
( O
1.4 O
) O
37 O
( O
25.5 O
) O
4 O
( O
4.7 O
) O
25 O
( O
25.5 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
1 O
( O
1.4 O
) O
8 O
( O
5.5 O
) O
1 O
( O
1.2 O
) O
0 O
( O
0 O
) O
Headache B-OSE_Labeled_AE
9 O
( O
12.5 O
) O
18 O
( O
12.4 O
) O
10 O
( O
11.8 O
) O
15 O
( O
15.3 O
) O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
1 O
( O
1.4 O
) O
0 O
( O
0 O
) O
0 O
( O
0 O
) O
6 O
( O
6.1 O
) O
* O
Insomnia B-OSE_Labeled_AE
2 O
( O
2.8 O
) O
9 O
( O
6.2 O
) O
4 O
( O
4.7 O
) O
13 O
( O
13.3 O
) O
Irritability B-OSE_Labeled_AE
5 O
( O
6.9 O
) O
16 O
( O
11 O
) O
4 O
( O
4.7 O
) O
7 O
( O
7.1 O
) O
Tic B-OSE_Labeled_AE
0 O
( O
0 O
) O
0 O
( O
0 O
) O
0 O
( O
0 O
) O
7 O
( O
7.1 O
) O
Adverse O
Reactions O
With O
the O
Long-Term O
Use O
of O
Daytrana O
In O
a O
long-term O
open-label O
study O
of O
up O
to O
12 O
months O
duration O
in O
326 O
children O
wearing O
Daytrana O
9 O
hours O
daily O
, O
the O
most O
common O
( O
> O
= O
10 O
% O
) O
adverse O
reactions O
were O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

A O
total O
of O
30 O
subjects O
( O
9.2 O
% O
) O
were O
withdrawn O
from O
the O
study O
due O
to O
adverse O
events O
and O
22 O
additional O
subjects O
( O
6.7 O
% O
) O
discontinued O
treatment O
as O
the O
result O
of O
an O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Other O
than O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
( O
5 O
subjects O
, O
1.5 O
% O
) O
was O
the O
only O
additional O
adverse O
reaction O
leading O
to O
discontinuation O
reported O
with O
a O
frequency O
of O
greater O
than O
1 O
% O
. O

In O
a O
long-term O
open-label O
study O
of O
up O
to O
6 O
months O
duration O
in O
162 O
adolescents O
wearing O
Daytrana O
9 O
hours O
daily O
, O
the O
most O
common O
( O
> O
= O
10 O
% O
) O
adverse O
reactions O
were O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
. O

A O
total O
of O
9 O
subjects O
( O
5.5 O
% O
) O
were O
withdrawn O
from O
the O
study O
due O
to O
adverse O
events O
and O
3 O
additional O
subjects O
( O
1.9 O
% O
) O
discontinued O
treatment O
as O
the O
result O
of O
an O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Other O
adverse O
reactions O
leading O
to O
discontinuation O
that O
occurred O
with O
a O
frequency O
of O
greater O
than O
1 O
% O
included O
affect O
lability O
and O
irritability O
( O
2 O
subjects O
each O
, O
1.2 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
In O
addition O
, O
the O
following O
adverse O
reactions O
have O
been O
identified O
during O
the O
postapproval O
use O
of O
Daytrana O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
Daytrana O
exposure O
. O

Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
accommodation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
: O
fatigue B-OSE_Labeled_AE
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
such O
as O
bleeding O
, O
bruising O
, O
burn O
, O
burning O
, O
dermatitis O
, O
discharge O
, O
discoloration O
, O
discomfort O
, O
dryness O
, O
eczema O
, O
edema O
, O
erosion O
, O
erythema O
, O
excoriation O
, O
exfoliation O
, O
fissure O
, O
hyperpigmentation O
, O
hypopigmentation O
, O
induration O
, O
infection O
, O
inflammation O
, O
irritation O
, O
pain O
, O
papules O
, O
paresthesia O
, O
pruritus O
, O
rash O
, O
scab O
, O
swelling O
, O
ulcer O
, O
urticaria O
, O
vesicles O
, O
and O
warmth O
. O

Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
generalized B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
and O
urticarial B-OSE_Labeled_AE
rashes I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
anaphylaxis B-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
convulsion B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
lethargy B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
in O
combination O
with O
serotonergic O
drugs O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
depression B-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
alopecia B-OSE_Labeled_AE
6.3 O
Adverse O
Reactions O
With O
Oral O
Methylphenidate O
Products O
Nervousness B-OSE_Labeled_AE
and O
insomnia B-OSE_Labeled_AE
are O
the O
most O
common O
adverse O
reactions O
reported O
with O
other O
methylphenidate O
products O
. O

In O
children O
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
during O
prolonged O
therapy O
, O
insomnia B-OSE_Labeled_AE
, O
and O
tachycardia B-OSE_Labeled_AE
may O
occur O
more O
frequently O
; O
however O
, O
any O
of O
the O
other O
adverse O
reactions O
listed O
below O
may O
also O
occur O
. O

Other O
reactions O
include O
: O
Cardiac B-NonOSE_AE
: O
angina B-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
pulse B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
or I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Immune B-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
with O
histopathological O
findings O
of O
necrotizing B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
and O
thrombocytopenic B-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
/ I-NonOSE_AE
Nutrition I-NonOSE_AE
: O
anorexia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
during O
prolonged O
therapy O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
drowsiness B-OSE_Labeled_AE
, O
rare O
reports O
of O
Tourette B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
psychosis I-OSE_Labeled_AE
Vascular B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased O
or O
decreased I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
arteritis I-OSE_Labeled_AE
and/or O
occlusion O
Although O
a O
definite O
causal O
relationship O
has O
not O
been O
established O
, O
the O
following O
have O
been O
reported O
in O
patients O
taking O
methylphenidate O
: O
Blood B-NonOSE_AE
/ I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
leukopenia B-OSE_Labeled_AE
and/or O
anemia B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
ranging O
from O
transaminase B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
to O
severe O
hepatic B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
: O
transient B-OSE_Labeled_AE
depressed I-OSE_Labeled_AE
mood I-OSE_Labeled_AE
Skin B-NonOSE_AE
/ I-NonOSE_AE
Subcutaneous I-NonOSE_AE
: O
scalp B-OSE_Labeled_AE
hair I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
: O
Very O
rare O
reports O
of O
neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
have O
been O
received O
, O
and O
, O
in O
most O
of O
these O
, O
patients O
were O
concurrently O
receiving O
therapies O
associated O
with O
NMS B-NonOSE_AE
. O

In O
a O
single O
report O
, O
a O
ten-year-old O
boy O
who O
had O
been O
taking O
methylphenidate O
for O
approximately O
18 O
months O
experienced O
an O
NMS B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
event I-OSE_Labeled_AE
within O
45 O
minutes O
of O
ingesting O
his O
first O
dose O
of O
venlafaxine O
. O

It O
is O
uncertain O
whether O
this O
case O
represented O
a O
drug-drug O
interaction O
, O
a O
response O
to O
either O
drug O
alone O
, O
or O
some O
other O
cause O
. O

Musculoskeletal B-NonOSE_AE
: O
rhabdomyolysis B-OSE_Labeled_AE

